axitinib

This page shows the latest axitinib news and features for those working in and with pharma, biotech and healthcare.

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

inhibitor Bavencio (avelumab) – both given in tandem with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib) – leading to them being touted as a potential new treatment standard for these patients.

Latest news

Merck’s Bavencio joins first-line kidney cancer face-off

The JAVELIN Renal 101 study reported at this week’s ESMO conference paired Merck’s immuno-oncology drug Bavencio (avelumab) with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), and revealed a
Keytruda hits survival targets in first-line kidney cancer

Pfizer’s VEGF-targeting Inlyta (axitinib), showing that the duo improved overall survival (OS) and progression-free survival (PFS) compared to Pfizer’s Sutent (sunitinib).
A look ahead to key trial readouts at ESMO

axitinib) – for this type of kidney cancer.
Pfizer’s plans for Inlyta go awry with failed adjuvant trial

The ATLAS study was testing whether VEGF inhibitor Inlyta (axitinib) given as an adjuvant treatment after surgery to remove the tumour could improve disease-free survival compared to placebo, but has
Good NICE news for Pfizer, but Dendreon drug rejected

NICE has given a final recommendation to Pfizer's new kidney cancer pill Inlyta (axitinib) - but has rejected Dendreon's prostate cancer treatment Provenge (sipuleucel-T).

More from news
Approximately 7 fully matching, plus 31 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Mirna hires former Pfizer director as CMO

Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Oncology drugs under AMNOG

Pfizer’ s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Scientific Director / Editorial Team Leader: Great salary and benefits

Medical Writers: Competitive Salary and Benefits

Director, Market Access / HEOR - North-West: Negotiable

Account Director: Excellent benefits

Events Manager – Med Comms – Surrey: Salary TBC

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Director: £48, 000 - £60, 000

Medical/ Scientific Director: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Consultant Health Economics - London / Oxford: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Medical Writer: Competitive Salary

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Medical Writers Required – Cheshire: DOE

Senior Medical Writer: Great salary and benefits

Account Manager / Senior Account Manager: 35, 000-40, 000

New Business Director - PR: Competitive Salary and benefits

Senior Account Executive, London, Medical Communications: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...